The effects of amiodarone on thyroid function

N. S. V. JAGGARAO
B.Sc., M.R.C.P.

E. N. GRUNDY
Ph.D.

JOANNA SHELDON
M.D., F.R.C.P.

R. VINCENT
B.Sc., M.R.C.P.

D. A. CHAMBERLAIN
M.D., F.R.C.P.

Departments of Cardiology, Medicine and Biochemistry, Royal Sussex County Hospital, Brighton BN2 5BE

Summary

The effects of amiodarone on thyroid function tests in 100 patients treated for 6 weeks to 8 years are reported. One patient became thyrotoxic and 10 developed latent or overt hypothyroidism. Twenty-five patients remained clinically euthyroid throughout, but had free thyroxine indices above the normal range. In these patients with apparently anomalous results, total tri-iodothyronine was normal in 19 cases and low in 1; conversely, free thyroxine was high in all 17 cases in which it was measured. Thyrotrophin releasing hormone (TRH) tests were abnormal in 4 of the 13 patients who had the test. Reverse tri-iodothyronine was significantly raised after 2 weeks amiodarone in 5 healthy subjects, but an equivalent amount of iodine in 9 healthy individuals did not significantly affect any of these tests. We believe that these changes are due in part to inhibition of peripheral conversion of thyroxine to tri-iodothyronine with diversion to reversed tri-iodothyronine.

Thyroid function tests should be checked once or twice a year in all patients on maintenance amiodarone. Tests indicating hypothyroidism are likely to be clinically relevant, whereas levels of thyroxine suggesting thyrotoxicosis may be misleading and do not usually imply the need to discontinue treatment with the drug.

Introduction

Amiodarone has been used widely in Europe as an antianginal and antiarrhythmic drug for more than 15 years (Vastesaeger, Gilloit and Rasson, 1967). Though available on a named-patient basis in Britain from 1973 (Chamberlain and Clark, 1977), it was licensed for limited clinical use only in early 1981. Acute toxicity does not occur readily with oral amiodarone and the drug is considered relatively safe. Unwanted effects during maintenance therapy include photosensitivity (Rosenbaum et al., 1976), minor ocular effects (François, 1969), and disorders of thyroid function (Massin et al., 1971).

We have noticed frequent discordance between the results of thyroid function tests and clinical status in our patients treated with amiodarone: we report our experience of the relationship gained over 8 years of observations and advance hypotheses which may account for apparently anomalous results.

Patients and methods

Serial thyroid function tests were performed on 100 patients treated with amiodarone for 6 weeks to 8 years. Their ages ranged from 33 to 92 years (mean 66 years). All were judged clinically euthyroid when amiodarone was started.

Amiodarone was administered in doses of 600 mg daily for 1 week, 400 mg daily for 1 week, and 200 mg daily subsequently. Once we appreciated how frequently the drug could affect thyroid hormone metabolism we measured thyroid function tests before treatment started and at least 6-monthly thereafter. A total of 53 patients had both baseline and follow-up tests. Most of our earlier patients who had been on treatment for up to 8 years were recalled for the purposes of this study, and 41 of them had only a single test at that time. The remaining 6 patients had serial tests which started after therapy had been commenced.

The free thyroxine index (FTI) was used as the routine screening test in all 100 patients, being derived from the total serum thyroxine (Ratcliffe et al., 1974) and residual thyroid hormone binding capacity of the serum measured by 'Thyopac 3'
(Amersham International). Additional thyroid function tests, performed in all patients with abnormal screening tests, included the serum free thyroxine (FT$_3$) (Grundy, 1979), the total serum tri-iodothyronine using the Amerlex T$_3$ radioimmunoassay kit (Amersham International), the serum thyroid binding globulin (TBG) (Grundy, 1979), and the thyrotrophin releasing hormone (TRH) test using 200 μg TRH with measurements of thyrotrophin (TSH) by radioimmunoassay (RIANEN TSH radioimmunoassay Kit, New England Nuclear).

In 5 healthy volunteers all these thyroid function tests together with measurement of serum reverse tri-iodothyronine (rT3) by radioimmunoassay (Mathur et al., 1979) were performed before and after 2 weeks treatment with 600 mg amiodarone daily.

In another 9 healthy subjects thyroid function was investigated similarly before and after treatment with 18 mg iodine daily, as diluted Lugol's iodine. This amount of iodine is equivalent to that released from 600 mg amiodarone (Broekhuysen, Laruel and Sion, 1969).

Statistical analyses were carried out using Student's t-test.

Results

Fifty-three of the 100 patients had FTI measurements both before and during treatment with amiodarone. In 38 patients the FTI rose and in 15 it fell on treatment, but overall there was a significant rise from a mean of 101 ± 20 (s.d.) before amiodarone to a mean of 123 ± 45 on amiodarone ($P<0.001$). Both these mean values were within the normal range.

During treatment the FTI rose above normal in 26 of the 100 patients, remained within the normal range in 70, and fell below normal in 4.

Patients with high FTI

Twenty-five of the 26 patients whose FTI was raised above normal on amiodarone remained clinically euthyroid throughout. This anomalous result was discovered at intervals ranging from 2 weeks to 4 years after starting treatment. Thyroid binding globulin was not abnormal in any of these patients. In 16 of these 25 patients the free thyroxine concentration was also measured and was raised in all of them (mean 33.7 nmol/litre ± 8 (s.d.) compared with normal range of 1–26 nmol/litre). By contrast the serum total tri-iodothyronine, measured in 20 of the 25 clinically euthyroid patients with raised FTI, was normal in every case except one in whom it was low (mean 1.8 nmol/litre ± 0.5 (s.d.) compared with normal range of 1.2–3.4 nmol/litre). Thirteen of these patients had had pre-amiodarone tri-iodothyronine measurements; in these there was a slight but insignificant fall during treatment with amiodarone, from a mean of 2.13 nmol/litre before treatment to 1.79 nmol/litre.

TRH tests were performed in 13 of the 25 clinically euthyroid patients with raised FTI and free thyroxine concentrations but with normal tri-iodothyronine levels. The TSH response to TRH was normal in 9 patients, impaired in 2, absent in one, and exaggerated in one.

One patient became clinically thyrotoxic after 20 months treatment. This patient, who had a small nodule in the thyroid, developed heat intolerance and lost 6.5 kg during the year before thyrotoxicosis was diagnosed. Her total serum thyroxine was 285 nmol/litre (normal 50–145), FTI 349 (normal 50–145) and she showed no rise of TSH in response to TRH. Nevertheless, her serum tri-iodothyronine remained normal at 2.6 nmol/litre (normal 1.2–3.4). Amiodarone was discontinued in this patient and in one other with a raised FTI for reasons unconnected with thyroid function. In both patients the FTI returned to normal after withdrawing the drug, and in the thyrotoxic patient a normal response to TRH was restored without the use of anti-thyroid therapy.

Patients with low FTI

Four patients became clinically hypothyroid between 24 and 79 months after starting treatment with amiodarone. All had a subnormal FTI and high basal TSH and were treated with thyroxine. Six other patients developed evidence of early hypothyroïdism with an FTI at the lower end of the normal range, but with raised basal TSH. The mean pre-treatment FTI in this group of 10 patients (79 ± 12 s.d.) was significantly lower than the mean pre-treatment FTI in the patients as a whole (102 ± 20) ($P<0.001$).

Healthy subjects

The results from 5 healthy subjects given 600 mg amiodarone daily for 2 weeks are shown in Table 1. In this group there was no significant change in FTI, free thyroxine, or tri-iodothyronine, but there was a significant rise in rT3 from a mean of 0.59 to 1.47 nmol/litre ($P<0.001$).

Nine normal subjects treated for 2 weeks with iodine equivalent to that released from 600 mg amiodarone showed no significant change in FTI, free thyroxine, tri-iodothyronine, or rT3, indicating that the rise in rT3 on amiodarone was not due simply to its iodine content.

Discussion

Amiodarone which contains 75 mg iodine per 200 mg of active substance, bears a structural similarity to thyroxine (Fig. 1). It might affect thyroid function for two reasons: firstly because of its iodine content, and
secondly because of its effect on peripheral thyroid hormone metabolism. Both hypothyroidism and hyperthyroidism have been described in patients on amiodarone (Massin et al., 1971).

![Thyroxine](image1)

**Fig. 1.** The chemical structures of thyroxine and amiodarone.

The iodine released from usual therapeutic doses of amiodarone would not, however, be likely to reduce appreciably thyroid hormone release in normal glands, though it could certainly do so in patients with Graves' disease (Wolff, 1969). The observations in our healthy subjects treated with iodine equivalent to that released from amiodarone confirmed this: no significant effect was demonstrable on thyroid function. Similarly, though iodine may provoke hyperthyroidism where there is pre-existing iodine deficiency it very rarely does so in normal glands (Savoie et al., 1975).

Amiodarone can also influence thyroid hormone metabolism by inhibiting the peripheral conversion of thyroxine to tri-iodothyronine, and enhancing its alternative pathway to reverse tri-iodothyronine, which is metabolically inactive (Burger et al., 1976).

Ten of our 100 patients on long-term amiodarone developed latent or overt hypothyroidism, and one developed hyperthyroidism. Our experience suggests that the development of hypothyroidism during amiodarone therapy is more likely to occur if there is some predisposition to it: the mean pre-amiodarone FTI, while within the normal range, was significantly lower in our patients who developed hypothyroidism than in the series as a whole.

The diagnosis of hyperthyroidism may present considerable difficulty in patients on amiodarone for two reasons. Firstly, the major clinical manifestation of the disease in the elderly may be cardiac, which will be modified by amiodarone; secondly, circulating thyroxine may be raised without clinical manifestations of thyrotoxicosis. Weight loss and heat intolerance were helpful features in our single thyrotoxic patient, whose FTI was also the highest recorded in our patients. The simultaneously normal tri-iodothyronine in this patient was unexpected, but her flat TSH response suggests that her intrapituitary tri-iodothyronine level was high. Perhaps intracellular tri-iodothyronine elsewhere was also high, producing her clinical hyperthyroidism. That the thyrotoxicosis in this patient was induced by amiodarone is inferred from its disappearance on withdrawal of the drug without the need for other therapy.

The striking feature in 25% of our patients was the raised FTI, though they remained euthyroid due to their normal tri-iodothyronine levels. This can be explained by amiodarone-induced inhibition of the conversion of thyroxine to tri-iodothyronine, with diversion of thyroxine to rT3. This was first postulated by Burger et al. in 1976, and has been described with other drugs including dexamethasone (Chopra et al., 1975), propranolol (Verhoeven et al., 1977), and radiographic contrast media such as iopanoic acid (Bürgi et al., 1976). This does not, however, explain the raised thyroxine levels in our patients on amiodarone, and in the 12 patients described by Pritchard et al. (1975). Raised thyroxine levels could be due to inhibition of hepatic uptake of thyroxine as has been observed with radiographic contrast agents.

**TABLE 1.** Change in thyroid function in 5 healthy subjects treated for 2 weeks with 600 mg amiodarone daily.

<table>
<thead>
<tr>
<th></th>
<th>Before amiodarone (± s.d.)</th>
<th>After amiodarone (± s.d.)</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean FTI (50-145)</td>
<td>100±5</td>
<td>112±13</td>
<td>NS</td>
</tr>
<tr>
<td>Mean FT4 (10-26 pmol/litre)</td>
<td>17±7±1-1</td>
<td>19±8±3-0</td>
<td>NS</td>
</tr>
<tr>
<td>Mean T3 (1-2-3-4 nmol/litre)</td>
<td>2±36±0-3</td>
<td>2±12±0-3</td>
<td>NS</td>
</tr>
<tr>
<td>Mean rT3 (0-29-0-69 mmol/litre)</td>
<td>0±59±0-19</td>
<td>1±47±0-38</td>
<td>P&lt;0-001</td>
</tr>
</tbody>
</table>

NS = Not significant
Normal values are shown in parentheses.
BROEKHUYSEN, Jaggarao was Fellowship. Visiting iodothyronine amiodarone rhythmias, In not on patients levels. ronine thyroxine these hyperthyroidism peripherally. variable on hyperthyroidism. yet thyroxine sufficient tri-iodothyronine tissues levels. of tri-iodothyronine spite in both exagerrated responses anomalous inhibition both di-iodothyronine and for the pathway Green thyroxine l’homme. chez serie des Therapie, 1976). In although from cases, should be helpful in circumstances this usually be due to a variable increase in circulating thyroxine and to a variable degree of inhibition of thyroxine to triodothyronine conversion both within the pituitary and peripherally.

In conclusion, although both hypothyroidism and hyperthyroidism may be induced by amiodarone, these are relatively rare complications. A high circulating thyroxine is not, however, uncommon in patients on amiodarone, though such patients usually remain clinically euthyroid with normal tri-iodothyronine levels. In these circumstances the drug need not be withdrawn, but regular observation is essential. In doubtfull cases, especially having regard to the influence of excess thyroid activity on cardiac arrhythmias, amiodarone should be discontinued. TRH tests are usually helpful but the serum triiodothyronine is probably the most helpful standard thyroid function test in this situation.

Acknowledgments

We thank Dr P. Marsden and Mr H. Keighley at Greenwich District General Hospital for measurements of reverse T3. Dr Jaggarao was in receipt of a British Heart Foundation Overseas Visiting Fellowship.

References


The effects of amiodarone on thyroid function.

N. S. Jaggarao, J. Sheldon, E. N. Grundy, R. Vincent and D. A. Chamberlain

Postgrad Med J 1982 58: 693-696
doi: 10.1136/pgmj.58.685.693

Updated information and services can be found at:
http://pmj.bmj.com/content/58/685/693

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/